Trial Profile
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms EmLiFa
- 20 Sep 2019 Results published in the Diabetes Care
- 11 Jun 2019 Primary endpoint (Change in liver fat content) has been met according to results presented at 79th Annual Scientific Sessions of the American Diabetes Association.
- 11 Jun 2019 Results (n=84) assessing effects empagliflozin on liver fat content were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.